{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:44:48Z","timestamp":1790077488297,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.prrv.2006.04.183","type":"journal-article","created":{"date-parts":[[2006,6,7]],"date-time":"2006-06-07T03:34:33Z","timestamp":1149651273000},"page":"S76-S79","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S1","title":["Other medications for aerosol delivery"],"prefix":"10.1016","volume":"7","author":[{"given":"Bruce K.","family":"Rubin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prrv.2006.04.183_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1155\/2003\/797054","article-title":"Cystic fibrosis: Bench to bedside 2003","volume":"10","author":"Rubin","year":"2003","journal-title":"Can Respir J"},{"key":"10.1016\/j.prrv.2006.04.183_bib2","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJM199306173282403","article-title":"Efficacy of aerosolized tobramycin in patients with cystic fibrosis","volume":"328","author":"Ramsey","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2006.04.183_bib3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1055\/s-2004-815667","article-title":"Aerosolized antibiotics in cystic fibrosis","volume":"24","author":"Sexauer","year":"2003","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2006.04.183_bib4","doi-asserted-by":"crossref","unstructured":"Ryan G, Mukhopadhyay S, Singh M. Nebulized anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Review 2003;(3):CD001021.","DOI":"10.1002\/14651858.CD001021"},{"key":"10.1016\/j.prrv.2006.04.183_bib5","doi-asserted-by":"crossref","unstructured":"Rubin BK, van der Schans CP. Eds. Therapy for Mucus Clearance Disorders. Biology of the Lung Series, Claude Lenfant (NIH) Executive editor. Marcel Dekker. March 2004.","DOI":"10.1201\/b14041"},{"key":"10.1016\/j.prrv.2006.04.183_bib6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1378\/chest.110.4.889","article-title":"Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease","volume":"110","author":"McCoy","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2006.04.183_bib7","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1164\/ajrccm.153.6.8665055","article-title":"Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations","volume":"153","author":"Wilmott","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2006.04.183_bib8","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1378\/chest.113.5.1329","article-title":"Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group","volume":"113","author":"O\u2019Donnell","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2006.04.183_bib9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/15412550500218148","article-title":"The role of airway secretions in COPD - Clinical applications","volume":"3","author":"Henke","year":"2005","journal-title":"J of COPD"},{"key":"10.1016\/j.prrv.2006.04.183_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1165\/rcmb.2003-0345OC","article-title":"MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions","volume":"31","author":"Henke","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prrv.2006.04.183_bib11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1183\/09031936.02.00025802","article-title":"Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis","volume":"19","author":"App","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2006.04.183_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev.biophys.29.1.545","article-title":"Molecular mechanisms controlling actin filament dynamics in nonmuscle cells","volume":"29","author":"Pollard","year":"2000","journal-title":"Annu Rev Biophys Biomol Struct"},{"key":"10.1016\/j.prrv.2006.04.183_bib13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1164\/ajrccm.157.3.9703059","article-title":"Improved clearability of cystic fibrosis sputum with dextran treatment in vitro","volume":"157","author":"Feng","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2006.04.183_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ppul.1098","article-title":"Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study","volume":"32","author":"Noone","year":"2001","journal-title":"Pediatr Pulmonol."},{"key":"10.1016\/j.prrv.2006.04.183_bib15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ppul.20192","article-title":"Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1\/phase 2 multicenter study in mild to moderate cystic fibrosis","volume":"39","author":"Deterding","year":"2005","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2006.04.183_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1465-9921-6-133","article-title":"Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients","volume":"6","author":"Griese","year":"2005","journal-title":"Respir Res"},{"key":"10.1016\/j.prrv.2006.04.183_bib17","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jama.278.17.1426","article-title":"Effects of aerosolized surfactant in patients with stable chronic bronchitis. A prospective randomized controlled trial","volume":"278","author":"Anzueto","year":"1997","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.prrv.2006.04.183_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0034-5687(90)90003-H","article-title":"Surfactant displaces particles toward the epithelium in airways and alveoli","volume":"80","author":"Schurch","year":"1990","journal-title":"Respir Physiol"},{"key":"10.1016\/j.prrv.2006.04.183_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M","article-title":"Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis","volume":"21","author":"Eng","year":"1996","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2006.04.183_bib20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1440-1843.2005.00659.x","article-title":"Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum","volume":"10","author":"Daviskas","year":"2005","journal-title":"Respirology"},{"key":"10.1016\/j.prrv.2006.04.183_bib21","doi-asserted-by":"crossref","unstructured":"Wark PA, McDonald V, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2005;(3):CD001506.","DOI":"10.1002\/14651858.CD001506.pub2"},{"key":"10.1016\/j.prrv.2006.04.183_bib22","doi-asserted-by":"crossref","unstructured":"Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2002;(1):CD002996.","DOI":"10.1002\/14651858.CD002996"},{"key":"10.1016\/j.prrv.2006.04.183_bib23","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(01)06412-1","article-title":"Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial","volume":"358","author":"Suri","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2006.04.183_bib24","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJM199509283331302","article-title":"A controlled study of adenovirus-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis","volume":"333","author":"Knowles","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2006.04.183_bib25","doi-asserted-by":"crossref","first-page":"124S","DOI":"10.1378\/chest.120.3_suppl.124S","article-title":"Gene therapy in cystic fibrosis","volume":"120","author":"Flotte","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2006.04.183_bib26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/089426802320282356","article-title":"Gene therapy for cystic fibrosis by means of aerosol","volume":"15","author":"Rochat","year":"2002","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.prrv.2006.04.183_bib27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1378\/chest.125.2.509","article-title":"Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial","volume":"125","author":"Moss","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2006.04.183_bib28","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1038\/sj.gt.3302372","article-title":"Lentivirus-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of cystic fibrosis","volume":"11","author":"Copreni","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.prrv.2006.04.183_bib29","first-page":"186","article-title":"Cationic lipid: pDNA complexes for the treatment of cystic fibrosis","volume":"1","author":"Eastman","year":"1999","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.prrv.2006.04.183_bib30","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.tibtech.2004.09.009","article-title":"Non-viral vectors in cystic fibrosis gene therapy: progress and challenges","volume":"22","author":"Montier","year":"2004","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.prrv.2006.04.183_bib31","doi-asserted-by":"crossref","first-page":"50393","DOI":"10.1074\/jbc.M309026200","article-title":"Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport","volume":"278","author":"Dawson","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.prrv.2006.04.183_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00024677-200504030-00001","article-title":"Inhaled insulins: their potential in the treatment of diabetes mellitus","volume":"4","author":"Harsch","year":"2005","journal-title":"Treat Endocrinol"},{"key":"10.1016\/j.prrv.2006.04.183_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-2796.1996.502836000.x","article-title":"Intrapulmonary administration of insulin to healthy volunteers","volume":"240","author":"Jedle","year":"1996","journal-title":"J Int Med"},{"key":"10.1016\/j.prrv.2006.04.183_bib34","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1378\/chest.114.6.1734","article-title":"The lung as an alternative route for delivery for insulin in controlling postprandial glucose levels in patients with diabetes","volume":"114","author":"Laube","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2006.04.183_bib35","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.2337\/diacare.28.8.1922","article-title":"Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: A 12-week, randomized, comparative trial","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.prrv.2006.04.183_bib36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-143-8-200510180-00005","article-title":"Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: A randomized, controlled trial","volume":"143","author":"Rosenstock","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.prrv.2006.04.183_bib37_1","first-page":"1161","article-title":"The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination","volume":"50","author":"Laube","year":"2005","journal-title":"Respir Care"},{"key":"10.1016\/j.prrv.2006.04.183_bib37_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.bioeng.4.100101.132311","article-title":"Bioengineering of therapeutic aerosols","volume":"4","author":"Edwards","year":"2002","journal-title":"Annu Rev Biomed Eng"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054206001825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054206001825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T06:18:58Z","timestamp":1555654738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054206001825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":38,"alternative-id":["S1526054206001825"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2006.04.183","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}